Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany
Abstract Background Recent therapeutic advancements for non-metastatic non-small cell lung cancer (NSCLC) have increased the need for real-world baselines against which future changes in patient management and clinical outcomes can be compared. Methods Data on patient characteristics, initial treatm...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-025-03715-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849333896284471296 |
|---|---|
| author | Alastair Greystoke Melinda J. Daumont Caroline Rault Hannah Baltus Philip Q. Ding Gabrielle Emanuel Stefano Lucherini Lien Vo Valeria M. Saglimbene Eleanor Ralphs Cátia Leal Minouk J. Schoemaker Alexander Katalinic Annika Waldmann Winson Y. Cheung |
| author_facet | Alastair Greystoke Melinda J. Daumont Caroline Rault Hannah Baltus Philip Q. Ding Gabrielle Emanuel Stefano Lucherini Lien Vo Valeria M. Saglimbene Eleanor Ralphs Cátia Leal Minouk J. Schoemaker Alexander Katalinic Annika Waldmann Winson Y. Cheung |
| author_sort | Alastair Greystoke |
| collection | DOAJ |
| description | Abstract Background Recent therapeutic advancements for non-metastatic non-small cell lung cancer (NSCLC) have increased the need for real-world baselines against which future changes in patient management and clinical outcomes can be compared. Methods Data on patient characteristics, initial treatment, and overall survival (OS) were derived from adult patients diagnosed with stage I-IIIC NSCLC (2010–2020) in a regional Canadian database (Oncology Outcomes [O2]), an English national registry (Cancer Analysis System [CAS]), and four regional German registries (VONKOdb) and retrospectively analyzed separately using analogous methodology. Results Data from 85,433 patients were analyzed. Stage at diagnosis varied, with proportions with stage I NSCLC ranging from 30.9% (VONKOdb) to 44.2% (O2) and with stage III disease from 36.9% (O2) to 48.5% (VONKOdb). Across the data sources, proportions receiving surgery ± other treatments were similar for stages I and II, but decreased through stages IIIA, IIIB, and IIIC (range, 24.7–42.7%, 4.6–21.8%, and 0.9–7.5%, respectively). Overall, 70.3–85.2% of patients received active treatment for NSCLC, with a trend toward lower proportions among those with stage III disease. Reached median OS tended to be longest in patients with resected stage I/II NSCLC (range, 28.8–128.0 months) and shortest in patients with stage IIIB/IIIC disease treated with systemic anticancer therapy (SACT) alone, radiotherapy alone, or SACT + palliative radiotherapy (range, 4.8–21.2 months). Conclusions These data provide insights into treatment pathways and survival outcomes before the widespread use of immunotherapy-based and targeted therapies and will serve as an important baseline for future evaluations of emerging treatments for patients with non-metastatic NSCLC. |
| format | Article |
| id | doaj-art-e8d11b531c3d48adaf7d4df9b3d5b25b |
| institution | Kabale University |
| issn | 1471-2466 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj-art-e8d11b531c3d48adaf7d4df9b3d5b25b2025-08-20T03:45:44ZengBMCBMC Pulmonary Medicine1471-24662025-05-0125112010.1186/s12890-025-03715-9Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and GermanyAlastair Greystoke0Melinda J. Daumont1Caroline Rault2Hannah Baltus3Philip Q. Ding4Gabrielle Emanuel5Stefano Lucherini6Lien Vo7Valeria M. Saglimbene8Eleanor Ralphs9Cátia Leal10Minouk J. Schoemaker11Alexander Katalinic12Annika Waldmann13Winson Y. Cheung14Newcastle Hospital and Newcastle UniversityWorldwide Health Economics & Outcomes Research, Bristol Myers SquibbData GnosisInstitute for Social Medicine and Epidemiology, University of LübeckDepartment of Oncology, University of CalgaryReal World Data Analytics Markets, Bristol Myers SquibbWorldwide Health Economics & Outcomes Research, Bristol Myers SquibbWorldwide Health Economics & Outcomes Research, Bristol Myers SquibbReal World Solutions, IQVIA LtdReal World Solutions, IQVIA LtdReal World Solutions, IQVIA LtdReal World Solutions, IQVIA LtdInstitute for Social Medicine and Epidemiology, University of LübeckInstitute for Social Medicine and Epidemiology, University of LübeckDepartment of Oncology, University of CalgaryAbstract Background Recent therapeutic advancements for non-metastatic non-small cell lung cancer (NSCLC) have increased the need for real-world baselines against which future changes in patient management and clinical outcomes can be compared. Methods Data on patient characteristics, initial treatment, and overall survival (OS) were derived from adult patients diagnosed with stage I-IIIC NSCLC (2010–2020) in a regional Canadian database (Oncology Outcomes [O2]), an English national registry (Cancer Analysis System [CAS]), and four regional German registries (VONKOdb) and retrospectively analyzed separately using analogous methodology. Results Data from 85,433 patients were analyzed. Stage at diagnosis varied, with proportions with stage I NSCLC ranging from 30.9% (VONKOdb) to 44.2% (O2) and with stage III disease from 36.9% (O2) to 48.5% (VONKOdb). Across the data sources, proportions receiving surgery ± other treatments were similar for stages I and II, but decreased through stages IIIA, IIIB, and IIIC (range, 24.7–42.7%, 4.6–21.8%, and 0.9–7.5%, respectively). Overall, 70.3–85.2% of patients received active treatment for NSCLC, with a trend toward lower proportions among those with stage III disease. Reached median OS tended to be longest in patients with resected stage I/II NSCLC (range, 28.8–128.0 months) and shortest in patients with stage IIIB/IIIC disease treated with systemic anticancer therapy (SACT) alone, radiotherapy alone, or SACT + palliative radiotherapy (range, 4.8–21.2 months). Conclusions These data provide insights into treatment pathways and survival outcomes before the widespread use of immunotherapy-based and targeted therapies and will serve as an important baseline for future evaluations of emerging treatments for patients with non-metastatic NSCLC.https://doi.org/10.1186/s12890-025-03715-9I-O OptimiseReal-world evidenceDatabaseRegistriesSurvivalTreatment patterns |
| spellingShingle | Alastair Greystoke Melinda J. Daumont Caroline Rault Hannah Baltus Philip Q. Ding Gabrielle Emanuel Stefano Lucherini Lien Vo Valeria M. Saglimbene Eleanor Ralphs Cátia Leal Minouk J. Schoemaker Alexander Katalinic Annika Waldmann Winson Y. Cheung Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany BMC Pulmonary Medicine I-O Optimise Real-world evidence Database Registries Survival Treatment patterns |
| title | Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany |
| title_full | Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany |
| title_fullStr | Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany |
| title_full_unstemmed | Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany |
| title_short | Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany |
| title_sort | real world treatment patterns and outcomes for patients with non metastatic non small cell lung cancer retrospective analyses in canada england and germany |
| topic | I-O Optimise Real-world evidence Database Registries Survival Treatment patterns |
| url | https://doi.org/10.1186/s12890-025-03715-9 |
| work_keys_str_mv | AT alastairgreystoke realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany AT melindajdaumont realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany AT carolinerault realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany AT hannahbaltus realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany AT philipqding realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany AT gabrielleemanuel realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany AT stefanolucherini realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany AT lienvo realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany AT valeriamsaglimbene realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany AT eleanorralphs realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany AT catialeal realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany AT minoukjschoemaker realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany AT alexanderkatalinic realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany AT annikawaldmann realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany AT winsonycheung realworldtreatmentpatternsandoutcomesforpatientswithnonmetastaticnonsmallcelllungcancerretrospectiveanalysesincanadaenglandandgermany |